181 related articles for article (PubMed ID: 35320352)
1. Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies.
Raoof S; Lee RJ; Jajoo K; Mancias JD; Rebbeck TR; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2022 Jun; 31(6):1139-1145. PubMed ID: 35320352
[TBL] [Abstract][Full Text] [Related]
2. Testing Whether Cancer Screening Saves Lives: Implications for Randomized Clinical Trials of Multicancer Screening.
Welch HG; Dey T
JAMA Intern Med; 2023 Nov; 183(11):1255-1258. PubMed ID: 37639251
[TBL] [Abstract][Full Text] [Related]
3. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
Owens L; Gulati R; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1298-1304. PubMed ID: 35477176
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies.
Doubeni CA; Lau YK; Lin JS; Pennello GA; Carlson RW
Cancer; 2022 Feb; 128 Suppl 4():883-891. PubMed ID: 35133658
[TBL] [Abstract][Full Text] [Related]
6. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.
Minasian LM; Pinsky P; Katki HA; Dickherber T; Han PKJ; Harris L; Patriotis C; Srivastava S; Weil CJ; Prorok PC; Castle PE
J Natl Cancer Inst; 2023 Mar; 115(3):250-257. PubMed ID: 36458902
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
9. Strong association between reduction of late-stage cancers and reduction of cancer-specific mortality in meta-regression of randomized screening trials across multiple cancer types.
Dai JY; Georg Luebeck E; Chang ET; Clarke CA; Hubbell EA; Zhang N; Duffy SW
J Med Screen; 2024 May; ():9691413241256744. PubMed ID: 38797981
[TBL] [Abstract][Full Text] [Related]
10. Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
Owens L; Gogebakan KC; Menon U; Gulati R; Weiss NS; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2023 Jun; 32(6):741-743. PubMed ID: 37259797
[TBL] [Abstract][Full Text] [Related]
11. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
12. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences.
Beer TM
Am J Manag Care; 2021 Dec; 27(19 Suppl):S347-S355. PubMed ID: 34870399
[TBL] [Abstract][Full Text] [Related]
13. Multicancer Early Detection: Learning From the Past to Meet the Future.
Etzioni R; Gulati R; Weiss NS
J Natl Cancer Inst; 2022 Mar; 114(3):349-352. PubMed ID: 34450655
[TBL] [Abstract][Full Text] [Related]
14. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies.
Etzioni R; Gulati R; Patriotis C; Rutter C; Zheng Y; Srivastava S; Feng Z
J Natl Cancer Inst; 2024 Feb; 116(2):189-193. PubMed ID: 37941446
[TBL] [Abstract][Full Text] [Related]
16. Measuring effectiveness of lung cancer screening: from consensus to controversy and back.
Strauss GM
Chest; 1997 Oct; 112(4 Suppl):216S-228S. PubMed ID: 9337293
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
